HK1040625B - 用於改善替普拉那维的药物动力学的方法 - Google Patents

用於改善替普拉那维的药物动力学的方法 Download PDF

Info

Publication number
HK1040625B
HK1040625B HK02102194.8A HK02102194A HK1040625B HK 1040625 B HK1040625 B HK 1040625B HK 02102194 A HK02102194 A HK 02102194A HK 1040625 B HK1040625 B HK 1040625B
Authority
HK
Hong Kong
Prior art keywords
tipranavir
ritonavir
bid
administration
effective amount
Prior art date
Application number
HK02102194.8A
Other languages
English (en)
Chinese (zh)
Other versions
HK1040625A1 (en
Inventor
J‧J‧菲瑞
J‧R‧鲍德温
M‧T‧柏林
J‧R‧鮑德溫
Original Assignee
法玛西雅厄普约翰美国公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法玛西雅厄普约翰美国公司 filed Critical 法玛西雅厄普约翰美国公司
Publication of HK1040625A1 publication Critical patent/HK1040625A1/xx
Publication of HK1040625B publication Critical patent/HK1040625B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK02102194.8A 1998-11-04 1999-10-29 用於改善替普拉那维的药物动力学的方法 HK1040625B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10696398P 1998-11-04 1998-11-04
US60/106,963 1998-11-04
PCT/US1999/021469 WO2000025784A1 (en) 1998-11-04 1999-10-29 Method for improving the pharmacokinetics of tipranavir

Publications (2)

Publication Number Publication Date
HK1040625A1 HK1040625A1 (en) 2002-06-21
HK1040625B true HK1040625B (zh) 2005-04-01

Family

ID=22314155

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102194.8A HK1040625B (zh) 1998-11-04 1999-10-29 用於改善替普拉那维的药物动力学的方法

Country Status (13)

Country Link
US (1) US6147095A (enExample)
EP (1) EP1126847A1 (enExample)
JP (1) JP2002528502A (enExample)
CN (1) CN1154491C (enExample)
AU (1) AU762349B2 (enExample)
BR (1) BR9914940A (enExample)
CA (1) CA2346131C (enExample)
CO (1) CO5160321A1 (enExample)
HK (1) HK1040625B (enExample)
MY (1) MY118526A (enExample)
PE (1) PE20001296A1 (enExample)
TW (1) TW580387B (enExample)
WO (1) WO2000025784A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
ATE381922T1 (de) * 2000-10-31 2008-01-15 Boehringer Ingelheim Pharma Perorale, selbst-emulgierende darreichungsformen von pyranon-proteaseinhibitoren
US6500963B2 (en) 2001-02-22 2002-12-31 Boehringer Ingelheim Pharma Kg Process for preparing optically active dihydropyrones
DE10108470A1 (de) * 2001-02-22 2002-09-05 Boehringer Ingelheim Pharma Verfahren zur Herstellung optisch aktiver Dihydropyrone
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
EP1575595A1 (en) * 2002-12-16 2005-09-21 Boehringer Ingelheim International GmbH Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
US20050020517A1 (en) * 2002-12-16 2005-01-27 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of HIV infection through combined administration of tipranavir and capravirine
WO2004087139A1 (en) * 2003-03-27 2004-10-14 Boehringer Ingelheim International Gmbh Antiviral combination of tipranavir and a further antiretroviral compound
AR045841A1 (es) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
CA2583187A1 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and etravirine
JP2008520672A (ja) * 2004-11-16 2008-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法
US20060128733A1 (en) * 2004-11-19 2006-06-15 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and reverset
US20060122220A1 (en) * 2004-11-19 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and UK-427,857
CA2585663A1 (en) * 2004-12-01 2006-06-08 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and sch-417690
JP2008521898A (ja) * 2004-12-01 2008-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビル及びｇｗ８７３１４０を共に投与することを含むｈｉｖ感染症の治療方法
US20060142344A1 (en) * 2004-12-01 2006-06-29 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and GW695634
KR101518079B1 (ko) 2007-03-12 2015-05-06 넥타르 테라퓨틱스 올리고머-프로테아제 억제제 컨주게이트
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
BR112012024522A2 (pt) * 2010-04-02 2017-08-08 Phivco 1 Llc combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
CN104160274A (zh) * 2011-05-30 2014-11-19 奥德特里克公司 通过照护点药物动力学曲线分析进行治疗药物监测和投配的方法与组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.

Also Published As

Publication number Publication date
MY118526A (en) 2004-11-30
PE20001296A1 (es) 2000-11-23
US6147095A (en) 2000-11-14
CO5160321A1 (es) 2002-05-30
CN1324237A (zh) 2001-11-28
AU762349B2 (en) 2003-06-26
JP2002528502A (ja) 2002-09-03
EP1126847A1 (en) 2001-08-29
CA2346131C (en) 2013-01-15
TW580387B (en) 2004-03-21
AU1440400A (en) 2000-05-22
WO2000025784A1 (en) 2000-05-11
HK1040625A1 (en) 2002-06-21
CN1154491C (zh) 2004-06-23
CA2346131A1 (en) 2000-05-11
BR9914940A (pt) 2001-07-10

Similar Documents

Publication Publication Date Title
CN1154491C (zh) 用于改善替普拉那维的药物动力学的方法
CN1290500C (zh) 逆转录病毒蛋白酶抑制剂的联合
Molla et al. Recent developments in HIV protease inhibitor therapy
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
HUP0103319A2 (hu) Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk
US20110003764A1 (en) Methods for Treatment of HIV or Malaria Using Combinations of Chloroquine and Protease Inhibitors
CN1684683A (zh) Hcv丝氨酸蛋白酶的有效抑制剂
US20160184332A1 (en) Medicament comprising a pharmaceutical combination of drugs
US5977086A (en) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
US20120283177A1 (en) Novel schedules for administering combination therapies useful for treating persons afflicted with the human immunodeficiency virus (hiv)
WO2015120057A1 (en) Pharmaceutical combinations against co-infection with hiv and tuberculosis
Lambert et al. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection
WO2011089166A1 (en) Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
Kubin et al. Antiretroviral agents
Fujiwara et al. Thiadiazole Derivatives: Highly Potent and Selective Inhibitors of Human Immunodeficiency Virus Type 1 (HIV‐1) Replications In Vitro
CN1537855A (zh) 炭球菌素及其制备方法和应用
EP1712231A2 (en) Method for improving the pharmacokinetics of tipranavir
Rawlins et al. Saquinavir
Threlkeld et al. Antiretroviral therapy
CN1901914A (zh) 利用氯喹和蛋白酶抑制剂的组合物治疗hiv或疟疾的方法
CN1180314A (zh) 血管紧张素转化酶抑制剂和降低副作用量的醛固酮拮抗剂的组合物
HK1085921A (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
HK1089091A (en) Compositions for down-regulation of ccr5 expression and methods of use therefor
CZ9904473A3 (cs) Prostředek k dopravení léčiva
CN1565442A (zh) 消旋去甲胡桐素a制备抗艾滋病毒类药物的应用

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20191028